t
Tissue Regenix Group plc confirmed that its CFO, Kirsten Lund, joined the board with immediate effect on 17 October 2025. Kirsten Lund, aged 41, holds 113,557 Tissue Regenix shares.
| Date | 17 Oct 2025 |
| Time | 07:00:10 |
| Category | Board changes |
| ID | 7496D |
Tissue Regenix Group plc
('Tissue Regenix' or the 'Group')
CFO joins Board
Tissue Regenix plc (AIM: TRX), the regenerative medical devices company, confirms that further to the announcement made on Thursday 16 October, Kirsten Lund, CFO, has joined the board with immediate effect.
Additional Disclosures Required under the AIM Rules for Companies
In accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules, Kirsten Mary Lund (aged 41) holds 113,557 Tissue Regenix shares. There is no further information to be disclosed in respect of the above appointment pursuant to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.
For more information:
|
Tissue Regenix Group plc |
||
|
Jay LeCoque, Executive Chairman |
via Walbrook PR |
|
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated Adviser and Broker) |
|
|
|
Geoff Nash/Giles Balleny/Edward Whiley |
Tel: +44 (0) 20 7466 5000 |
|
|
Nigel Birks - Life Science Specialist Sales |
|
|
|
Harriet Ward - ECM |
|
|
|
|
|
|
|
Walbrook PR (Financial PR and IR) |
Tel: +44 (0)20 7933 8780 or [email protected] |
|
|
Alice Woodings / Paul McManus |
Mob: +44 (0)7407 804 654 / +44 (0)7980 541 893 |
|
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries and wound care.